Industry Overview

China DNA vaccine market was valued at $62.2 million in 2025 and is projected to reach $93.7 million by 2035, growing at a CAGR of 4.3% during the forecast period (2026–2035). The China DNA Vaccine market is growing due to sustained investment in nucleic acid vaccine research and the increasing need for rapid, scalable immunization platforms targeting infectious diseases and oncology indications. Plasmid DNA vaccines offer advantages in design flexibility, thermal stability, and manufacturing efficiency, which support faster response timelines compared with conventional vaccine approaches. This technological adaptability has strengthened their relevance in both human and animal health segments, particularly where emerging pathogens and livestock disease control require accelerated development cycles. In parallel, advancements in plasmid DNA delivery technology have improved cellular uptake and immunogenic response, addressing earlier limitations related to efficacy and consistency.

Market Dynamics

Expansion of Domestic Plasmid DNA Manufacturing Capacity to Strengthen Supply Security

The China DNA vaccine market is witnessing expansion in domestic plasmid DNA manufacturing capacity to reduce reliance on imported raw materials and contract production. Companies are investing in GMP-compliant plasmid production facilities to support both clinical-stage and commercial-scale human and animal DNA vaccines. This capacity build-out is particularly relevant for infectious disease and oncology applications, where uninterrupted supply is critical for trial continuity and product rollout. Strengthened upstream integration also enables better cost control and quality standardization across vaccine batches. As a result, localized plasmid DNA production is emerging as a structural growth driver within the market.

Increasing Application of DNA Vaccine Platforms in Veterinary and Livestock Health

Rising demand for disease prevention in livestock and companion animals is contributing to the expansion of the animal DNA vaccine segment in China. DNA vaccines offer practical advantages in veterinary settings, including stability, ease of large-scale production, and suitability for rapid strain updates. This is particularly important for managing transboundary animal diseases that affect poultry, swine, and aquaculture industries. Regulatory support for innovative veterinary biologics is further encouraging product development and pilot commercialization. Consequently, the integration of DNA vaccine technology into animal health programs is strengthening the broader market foundation.

Market Segmentation

• Based on the type, the market is segmented into animal DNA vaccine, and human DNA vaccine.
• Based on the technology, the market is segmented into plasmid DNA vaccines technology, and plasmid DNA delivery technology.
• Based on the application, the market is segmented into oncology, infectious diseases, and others.

Human DNA Vaccine Segment Growth Driven by Clinical Expansion

The Human DNA vaccine segment represents a leading sub-segment within the China DNA vaccine market, driven primarily by increased clinical research targeting infectious diseases and oncology indications. Rising focus on rapid-response vaccine platforms has positioned plasmid DNA vaccines as viable candidates for emerging and re-emerging pathogens. In oncology, DNA-based immunotherapies are being evaluated for their ability to induce targeted immune responses with favorable safety profiles. The presence of domestic developers with in-house plasmid production capabilities further supports translational progress from early research to clinical stages.

Plasmid DNA Delivery Technology Advancements Driving Adoption

The Plasmid DNA delivery technology segment is emerging as a critical growth area in the China DNA vaccine market, supported by technological advancements that improve intracellular delivery and antigen expression. Effective delivery remains central to enhancing immune response consistency, particularly in human therapeutic applications. Innovations in electroporation systems and formulation strategies are addressing historical limitations associated with low transfection efficiency. These improvements are increasing the clinical viability of DNA vaccines across both infectious disease and oncology applications.

Market Players Outlook

The major companies operating in the China DNA vaccine market include Advaccine Biopharmaceuticals Suzhou Co., Ltd., CanSino Biologics Inc., China National Pharmaceutical Group Co., Ltd. (Sinopharm), Shenzhen Kangtai Biological Products Co., Ltd., WuXi Biologics (WuXi Vaccines), among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In January 2026, Fosun Wanbang and Beijing Orient Biopharmaceutical formed a strategic partnership, with Fosun Wanbang securing exclusive commercialization rights for VGX-3100 in Greater China.
• In 2021, Advaccine expanded its partnership with INOVIO for the global Phase 3 trial of the INO-4800 COVID-19 vaccine. Advaccine, equipped with large-scale GMP DNA vaccine manufacturing facilities and a new Chinese vaccine manufacturing license, aims to increase production to meet global demand. Advaccine has co-developed INO-4800 with INOVIO, sponsoring Phase 1 and 2 trials in China.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the China DNA vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.